Fig. 1
From: Streptozotocin-induced hyperglycemia unmasks cardiotoxicity induced by doxorubicin
Streptozotocin-induced hyperglycemia aggravates cardiac dysfunction and mortality induced by doxorubicin. (A) Schematic representation of the protocol used in vivo. (B) Kaplan-Meyer plot of mice surviving during the in vivo experimental protocol in the 4 groups of mice treated with saline (Ctl), doxorubicin (Dox), streptozotocin (STZ) or both (Dox-STZ). (C) Cardiac function evaluated by fractional shortening measured by transthoracic echocardiography (TTE) of mice after doxorubicin treatment (represented arrow Dox on the x-axis) and type 1 diabetes (represented by Stz on the x-axis). (D) Cleaved caspase 3 protein expression in the cardiac tissue evaluated by western blot. (E, F) mRNA expression of Bax and Bcl2, respectively measured in the cardiac tissue par RT-qPCR. *p < 0.05, **p < 0.01 and ***p < 0.001.
